Drug Development

Johnson & Johnson unveils three-year Tremfya data for Crohn's disease, highlighting bold fistula results and framing a new battle over trial reporting.

As ORIC Pharmaceuticals prepares to unveil pivotal clinical data in Madrid, the focus shifts to brain-penetrant lung cancer therapies and epigenetic modulation.

As antimicrobial resistance threatens global health, Paratek Pharmaceuticals leverages a $304 million BARDA contract to expand NUZYRA's clinical footprint.

A new monoclonal antibody targeting the root cause of Graves' and thyroid eye disease could upend a market dominated by cumbersome infusions.

As Chinese medicine seeks global credibility, a recent Singapore forum highlights the complex push to translate ancient theory into modern clinical guidelines.

Basel-based biotech Nouscom just raised €120 million to fund a pivotal trial for NOUS-209, shifting oncology from treating tumors to intercepting them entirely.

By targeting the physical mechanics of tumors rather than biochemical pathways, Myosin Therapeutics aims to conquer glioblastoma and court investors in NYC.

Despite recent clinical setbacks, Alector's $75 million premium offering signals strong institutional faith in its blood-brain barrier technology.

Cyrano Therapeutics reports positive Phase 2 data for a repurposed asthma drug to treat post-viral smell loss, but regulatory hurdles loom for Phase 3.

Adial Pharmaceuticals appoints the architect behind the first FDA-approved AhR agonist to lead its new ulcerative colitis drug into 2027 clinical trials.

George Millen explores how Montefiore Einstein's newly minted cancer leadership team is turning urban health disparities into a strategic research advantage.

Transcripta Bio and Mayo Clinic are combining artificial intelligence and living patient data to map ALS, highlighting how institutions fuel precision medicine.

Expression Therapeutics secures a $2M NCI grant to advance a novel gamma delta T-cell therapy, turning immune cells into localized drug factories for kids.

An N-of-3 pilot study reveals how Krystal Biotech's new intratumoral immunotherapy could replace lifelong surgeries with systemic immune clearance.

Amidst geopolitical headwinds, WuXi XDC's double win at the 2026 World ADC Awards highlights a relentless drive to dominate the bioconjugate supply chain.

Merz completes Phase III migraine trial recruitment six months early, signaling a strategic threat to AbbVie’s dominance with its purified neurotoxin, XEOMIN.

Phanes Therapeutics has advanced its first-in-class bispecific antibody into colorectal cancer trials, testing a novel mechanism to bypass systemic toxicity.

Pilatus Biosciences doses its first Hong Kong patient with PLT012, signaling a strategic shift toward metabolic immunotherapies and Asian clinical hubs.

By halving infusion volumes for immunodeficiency patients, Takeda's experimental TAK-881 is not just treating a disease—it is giving people their time back.

Elion Therapeutics secures global rights to EL777, an inhaled antifungal aiming to prevent deadly infections in a growing immunocompromised population.